FCX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

FCX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit GlobeNewswire December 06, 2025 SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly […]

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

(HKSE:1877.HK),(Shenzhen:688180.SS), Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients GlobeNewswire December 06, 2025 Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate

SRN Advisors, LLC Announces Reorganization of Siren DIVCON Dividend Defender ETF into and with Siren DIVCON Leaders Dividend ETF

SRN Advisors, LLC (SRN) announced today that the Siren DIVCON Dividend Defender ETF (CBOE: DFND), an index-based exchange-traded fund (“ETF”) managed by SRN, will reorganize into and with the Siren DIVCON Leaders Dividend ETF (CBOE: LEAD) (the “Funds”), also an index-based ETF managed by SRN. The reorganization was approved by the Board of Trustees (the

Transfeero Closes 2025 With Record Growth and a Global Presence in 100 Countries

Bozen, Italy–(Newsfile Corp. – December 5, 2025) – Transfeero ends 2025 as one of the strongest years in its history, solidifying its position as a leading global provider of private transportation services. The platform designed to connect travelers seeking reliable and convenient mobility solutions with a worldwide network of professional drivers and licensed transport companies

Vincenzo’s brand Sweet and Savory Mix recalled due to Salmonella

Product:Sweet and Savory Mix Issue: Food – Microbial contamination – Salmonella Distribution:Ontario Online link SOURCE Canadian Food Inspection Agency (CFIA) https://rt.newswire.ca/rt.gif?NewsItemId=C3672&Transmission_Id=202512052104CANADANWWEB______C3672&DateId=20251205

PCs for People Announces Departure of Cofounder and CEO Casey Sorensen After 18 Years of Leadership

PCs FOR PEOPLE announced today that Cofounder and CEO, Casey Sorensen, is departing from his role effective December 26, 2025. Sorensen, with the nonprofit since 2008, turned a simple idea of getting computers to low-income families into a self-sustaining model, where each region funds its own start-up costs. “Casey worked tirelessly to shape PCs for

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual Meeting Pivotal Phase 3 ARISE trial evaluating solengepras as an adjunctive treatment in Parkinson's disease is underway and actively enrolling patients BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) — Cerevance, a clinical-stage biopharmaceutical

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson's Disease GlobeNewswire December 06, 2025 Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual Meeting Pivotal Phase 3 ARISE trial evaluating

FLY INVESTOR NOTICE: Firefly Aerospace Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY): (i) securities between August 7, 2025 and September 29, 2025, inclusive (the “Class Period”); and/or (ii) common stock pursuant and/or traceable to Firefly Aerospace's offering documents issued in connection with Firefly Aerospace's August 7,

Scroll to Top